Titration of betaine therapy to optimize therapy in an infant with 5,10-methylenetetrahydrofolate reductase deficiency.
Eur J Pediatr
; 169(2): 241-3, 2010 Feb.
Article
em En
| MEDLINE
| ID: mdl-19434424
ABSTRACT
Betaine therapy was given for 2 years to a 2-year-old boy with 5,10-methylenetetrahydrofolate reductase deficiency. Used as a methyl donor to lower homocysteine levels through methylation of methionine, betaine has been reported to be effective in treating homocystinuria. Satisfactory biochemical and clinical responses were obtained with the following regimen betaine started in the newborn period at increasing doses to reach 1 g given six times a day. It is suggested that frequent administration of a moderate dose may provide clinical and biochemical benefit.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Betaína
/
5,10-Metilenotetra-Hidrofolato Redutase (FADH2)
/
Deficiência de Ácido Fólico
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Child, preschool
/
Humans
/
Male
Idioma:
En
Revista:
Eur J Pediatr
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Turquia